User:Mr. Ibrahem/Ropinirole

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Ropinirole
Clinical data
Trade namesRequip, Repreve, Ronirol, others
AHFS/Drugs.comMonograph
MedlinePlusa698013
Pregnancy
category
  • C
Routes of
administration		By mouth
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability50%[1]
MetabolismLiver (CYP1A2)[1]
Elimination half-life5-6 hours[1]
Identifiers
  • 4-[2-(Dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one
Chemical and physical data
FormulaC16H24N2O
Molar mass260.381 g·mol−1
3D model (JSmol)
  • O=C2Nc1cccc(c1C2)CCN(CCC)CCC
  • InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19) checkY
  • Key:UHSKFQJFRQCDBE-UHFFFAOYSA-N checkY
  (verify)

Ropinirole, sold under the brand name Requip among others, is a medication used to treat Parkinson's disease (PD) and restless legs syndrome (RLS).[3] In PD the dose needs to be adjusted to the effect and treatment should not be suddenly stopped.[3] It is taken by mouth.[4]

Common side effects include sleepiness, vomiting, and dizziness.[4] Serious side effects may include pathological gambling, low blood pressure with standing and hallucinations.[4][3] Use in pregnancy and breastfeeding is of unclear safety.[5] It is a dopamine agonist and works by triggering dopamine D2 receptors.[4]

It was approved for medical use in the United States in 1997.[4] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about £34 per month as of 2019.[3] In the United States the wholesale cost of this amount is about US$7.90.[6] In 2017, it was the 108th most commonly prescribed medication in the United States, with more than six million prescriptions.[7][8]

References[edit]

  1. ^ a b c Tompson, Debra J.; et al. (2007). "Steady-State Pharmacokinetic Properties of a 24-Hour Prolonged-Release Formulation of Ropinirole: Results of Two Randomized Studies in Patients with Parkinson's Disease". Clinical Pharmacokinetics. 29 (12): 2654–66. doi:10.1016/j.clinthera.2007.12.010. PMID 18201581.
  2. ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 6 September 2020.
  3. ^ a b c d e British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 419–420. ISBN 9780857113382.
  4. ^ a b c d e "Ropinirole Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  5. ^ "Ropinirole Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
  6. ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
  7. ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
  8. ^ "Ropinirole Hydrochloride - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Ropinirole&oldid=1076679159"